Novartis AG NOVN, +0.47% NVS, +2.05% said Monday that a study on a drug to treat adult paroxysmal nocturnal hemoglobinuria, a red blood cell condition, has met its two primary Read more
Novartis AG NOVN, +0.47% NVS, +2.05% said Monday that a study on a drug to treat adult paroxysmal nocturnal hemoglobinuria, a red blood cell condition, has met its two primary Read more